Hint mode is switched on Switch off
For swift navigation between sections

Harpoon Therapeutics
LEI 549300VFZL0TEVXILA36

PDF download

Choose all Reset all
Download Cancel
Organization name
Harpoon Therapeutics Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Harpoon is a clinical-stage immuno-oncology company developing a novel class of T cell engagers that unleash the natural power of the T cells to fight cancer and other diseases.

Awards

News

11/03/2024 Harpoon Therapeutics: Pursuant To The Merger Agreement, At The Effective Time Of The Merger (the Effective Time ), (a) Each Share Of Harpoon Common Stock (other Than (i) Shares Held In The Treasury Of Harpoon Or Owned By Merck Or Merger Sub Or Any Direct Or Indirect Wholly Owned Subsidiary Of Merck Or Harpoon Immediately Prior To The Effective Time And (ii) Shares Held By Stockholders Who Have Perfected Their Statutory Rights Of Appraisal Under Section 262 Of The Delaware General Corporation Law (clauses (i) And (ii) Together, The Excluded Shares )) Was Cancelled And Converted Automatically Into The Right To Receive $23.00 In Cash, Without Interest, With Respect To Such Shares Of Harpoon Common Stock (the Merger Consideration ), Subject To Applicable Withholding Taxes, And (b) Each Share Of Series A Preferred Stock, Par Value $0.0001 Per Share, Of Harpoon (the Preferred Shares ) Issued And Outstanding Immediately Prior To The Effective Time (other Than Any Excluded Shares) Was Cancelled And The Holder Is Entitled To Receive $3,577.77 In Respect Of Each Preferred Share Determined In Accordance With The Terms Of The Preferred Shares, Subject To Applicable Withholding Taxes, Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Material Modification To Rights Of Security Holders, Change In Control Of Registrant, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits
25/01/2024 Harpoon Therapeutics: Other Events, Financial Statements And Exhibits
07/01/2024 Harpoon Therapeutics: Entry Into A Material Definitive Agreement, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensation Arrangements Of Certain Officers, Regulation Fd, Financial Statements And Exhibits
26/11/2023 Harpoon Therapeutics: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Financial Statements And Exhibits
24/11/2023 Harpoon Therapeutics: Other Events, Financial Statements And Exhibits
All organization news

Documentation

IFRS/US GAAP reports

2023
I q eng
II q eng
III q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300VFZL0TEVXILA36
  • SIC
    2836 BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
  • CIK
    0001708493
  • EIN
    47-3458693
Registration is required to get access.